GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

Are All Stem Cell Treatments the Same?

No. Stem cell treatments differ in cell type, tissue source, processing, dose, delivery route, medical purpose, evidence, and regulatory status. Two treatments are not interchangeable just because both use the words “stem cells.” The useful comparison is between the exact products and procedures, not their shared label.

For example, the US Food and Drug Administration (FDA) approved Ryoncil, a donor bone marrow-derived mesenchymal stromal cell (MSC) product, in December 2024 for steroid-refractory acute graft-versus-host disease in children aged two months and older Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host. That is different from a blood stem cell transplant used to restore blood formation after intensive treatment for selected cancers, blood disorders, and autoimmune diseases Stem cell transplant. Neither establishes that a clinic’s fat-derived injection will treat an arthritic knee. The FDA’s consumer warning, last updated in April 2024, specifically cautions against unapproved regenerative products marketed for osteoarthritis Important patient and consumer information about regenerative medicine therapies.

Are All Stem Cell Treatments the Same?

When comparing offers, ask: what product, for which condition, at what dose, by which route, supported by which human studies, and under which local rules? Price, testimonials, and travel distance cannot answer those questions.

This guide compares regulator documents and published research, not individual clinics. Its worked examples use the FDA’s Ryoncil approval materials and the published abstract of the Garza knee trial. They are not patient case reports or firsthand clinical experience. The Garza full paper was not available for this review, so details absent from its abstract are not treated as verified.

The label is not the product

A stem cell can self-renew and develop into specialized cells. But a treatment sold as stem cell therapy may contain blood-forming cells, stromal cells, a mixed tissue-derived cell preparation, or even a cell-free product.

Blood-forming stem cells — hematopoietic stem cells — drive blood stem cell transplants (also called HSCT). They rebuild the marrow so it can make red cells, white cells, and platelets again after intensive treatment Stem cell transplant. This is an established procedure for selected patients. Recovery takes months, and the immune system can need 1 to 2 years to recover after a donor (allogeneic) transplant. The preparative regimen and the transplant itself can bring infection, bleeding, infertility, organ damage, and — after a donor transplant — graft-versus-host disease (GVHD) Stem cell transplant.

Mesenchymal stromal cells, often called mesenchymal stem cells, are a different category. Preparations can originate from bone marrow, fat, umbilical cord, and other tissues. The International Society for Cellular Therapy’s minimum criteria for cultured MSCs include adherence to plastic, a defined surface-marker profile, and the ability to differentiate into bone, fat, and cartilage cells under laboratory conditions 14653240600855905. Meeting those criteria does not establish clinical effectiveness.

Adipose stromal vascular fraction (SVF) is a mixed cell preparation from fat, not a purified, culture-expanded MSC product. In the knee trial discussed below, fat was collected by liposuction, processed, and injected during the same visit 32109160. Evidence for that preparation cannot simply be transferred to a different lab-grown MSC product.

Perinatal sources cover cord blood, amniotic fluid, amnion, and Wharton’s jelly. Cord blood supplies blood-forming stem cells; Wharton’s jelly, amnion, and amniotic fluid are different starting materials, and products made from them cannot swap in for cord blood. An FDA-approved cord blood product is no blanket approval for every cord-derived product Important patient and consumer information about regenerative medicine therapies.

Exosomes are tiny vesicles released by cells, not cells themselves. An exosome preparation is not a stem cell transplant. The FDA’s consumer warning includes unapproved exosome products among its safety concerns Important patient and consumer information about regenerative medicine therapies.

What it is called What the patient may receive Example of status
Blood stem cell transplant Blood-forming stem cells from bone marrow, blood, or umbilical cord Established for selected cancers, blood disorders, and some autoimmune diseases Stem cell transplant
Mesenchymal stromal cell product Lab-grown cells, usually from bone marrow, fat, cord, or another tissue Ryoncil (donor bone marrow MSC) has a US approval for pediatric steroid-refractory acute GVHD Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host; Temcell’s Japanese approval concerns acute GVHD after HSCT 000215658.pdf
Adipose stromal vascular fraction A mixed cell population from fat, injected during the same visit in the cited trial Studied in knee osteoarthritis 32109160; the FDA’s April 2024 consumer warning cautions against unapproved regenerative products for this use Important patient and consumer information about regenerative medicine therapies
Cord blood, amniotic fluid, amnion, or Wharton’s jelly product Different cell populations or tissue-derived preparations Approval of a cord blood product does not cover a different cord-tissue or amniotic product; verify the exact product and indication Important patient and consumer information about regenerative medicine therapies
Exosome product Cell-derived vesicles, not living cells The FDA warns about unapproved exosome products; these are not substitutes for a transplant Important patient and consumer information about regenerative medicine therapies

Don’t read the table as a ranking. Two offers at the same price can differ in cell number, viability, release testing, and route. A same-day SVF injection and a lab-grown donor MSC infusion involve different collection, processing, testing, and risk.

Consider this hypothetical offer, not a patient account:

“We will give you 100 million of your own stem cells intravenously for knee arthritis.”

It gives a count, a source, and a route, but leaves out the cell identity, processing, viability, supporting trial, and complication plan. Ask for the product specification and a study using the same route in people with your diagnosis. If the quoted count includes several cell types, ask how many are the cells the clinic claims will provide the benefit. A large total count does not resolve those gaps.

What changes from one treatment to the next

Use the following differences to compare written treatment plans side by side.

Cell type and tissue source

The cells come from you (autologous) or from a donor (allogeneic). Neither origin guarantees safety. Your own cells avoid donor-derived GVHD, but collection, contamination, processing, and administration can still cause harm Important patient and consumer information about regenerative medicine therapies. Donor blood stem cell transplants require compatibility assessment and can cause GVHD; those risks should not be applied indiscriminately to every donor MSC product Stem cell transplant. The autologous versus allogeneic distinction is a starting point, not a complete risk assessment.

Tissue source alone is not a product specification. Ask whether the preparation is a selected and cultured cell population or a mixed cell preparation such as SVF, and whether its identity matches the cited research.

Processing and dose

Ask which collection, culture, freezing, transport, and testing steps apply to the proposed product. For a cultured preparation, request the passage number, storage conditions, and release specifications from the provider or its cell processing center in Japan. Do not assume that products made using different processes are equivalent merely because they started with the same tissue.

Processing carries its own safety risks: the FDA warns that unapproved regenerative products have been tied to bacterial infections, including life-threatening bloodstream infections, and to contamination with bacteria, viruses, or mold during preparation Important patient and consumer information about regenerative medicine therapies. A spotless clinic room cannot rescue a contaminated cell product.

Compare the viable cell dose and schedule, as well as the product’s potency, meaning its measured biological activity. Ryoncil’s initial course consists of intravenous infusions twice weekly for four weeks: eight infusions, with additional treatment possible depending on response Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host. Temcell’s 2015 Japanese review specifies 2 million cells per kilogram by intravenous infusion, twice weekly for four weeks, with weekly treatment for an additional four weeks depending on symptoms 000215658.pdf.

The Garza study used a single knee injection and compared high- and low-dose SVF with placebo. It assessed both symptoms and cartilage thickness on MRI; symptom improvement did not establish cartilage repair 32109160. A dose-response pattern in that small trial does not mean that more cells are always better across products.

Route of delivery

An intravenous infusion introduces cells into the circulation. An intra-articular injection places them inside a joint, while an intrathecal injection enters the fluid surrounding the brain and spinal cord. None of those descriptions, by itself, proves where cells will persist or what benefit they will produce. Do not assume that IV cells will reach or repair a particular organ, or that cells injected into a joint will remain there. Ask for human evidence using the proposed route, rather than borrowing results from another procedure.

The condition and its stage

Evidence must match the diagnosis, severity, prior treatment, and timing of the proposed intervention.

Ryoncil’s approval covers a pediatric transplant complication, not arthritis or a general “immune reset” Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host. Stemirac’s 2018 conditional approval concerned traumatic spinal cord injury at American Spinal Injury Association Impairment Scale (AIS) grades A, B, or C. Its review specifies aiming to collect bone marrow within 31 days of injury, then administering the manufactured product as early as possible. That early-injury pathway cannot be treated as evidence for a chronic injury years later 000231946.pdf.

What “approved” does and does not mean

An approval concerns a specified product and indication, with defined labeling and manufacturing requirements. It does not automatically cover another preparation made from the same tissue. Approval in one country also does not establish authorization in another.

Ryoncil illustrates why the details matter. Its multicenter, single-arm study enrolled 54 children with steroid-refractory acute GVHD after a donor blood stem cell transplant. At day 28, 16 children (30%) had a complete response and 22 (41%) a partial response Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host. These are response rates in a severely ill group, not cure rates and not a placebo-controlled estimate of benefit.

The prescribing information reports serious adverse reactions in 35 of 54 participants (65%), including fever, respiratory failure, and staphylococcal bloodstream infection, with adverse-reaction reporting extending through 100 days after treatment. The label warns about hypersensitivity and infusion reactions, transmission of infectious agents, and ectopic tissue formation Download?attachment. The 65% figure is not the risk of every MSC treatment and does not, without a comparator, quantify how much risk treatment added to this underlying illness.

The FDA’s older consumer warning is useful for understanding unapproved-product risks, but it is not a complete inventory of current approvals. For a treatment decision, check the exact product’s current labeling. “FDA-approved stem cells” without a product name and indication is not enough.

The FDA has received reports of blindness, tumor formation, and serious infections associated with unapproved regenerative products. It also warns that listing a study on ClinicalTrials.gov, or registering a firm with the FDA, does not make a product legally marketed Important patient and consumer information about regenerative medicine therapies.

What Japan’s rules do and do not mean

In Japan, a filed treatment plan and a product marketing approval are different regulatory pathways. Under the Act on the Safety of Regenerative Medicine, covered medical practice and research require a provision plan and the applicable risk-based procedures. These include committee review, reporting, inspections, and powers to require changes or suspend provision Plan. The Pharmaceuticals, Medical Devices, and Other Therapeutic Products Act (PMD Act) regulates commercialization of regenerative medical products 0003.

Conditional and time-limited approval permits marketing subject to specified conditions and further evaluation. It should not be described as full approval or as proof that all questions about efficacy have been settled 0003.

A provision plan number is not marketing approval and does not, by itself, establish clinical benefit. Committee review and reporting provide oversight, but they are not substitutes for studies of the exact intervention. When checking Japan’s regenerative medicine registration framework, distinguish the plan number and risk class from a product’s approval and its supporting evidence.

The PMDA’s review archive, checked October 27, 2026, illustrates different outcomes: Temcell received approval in 2015 for acute GVHD; Stemirac received conditional and time-limited approval in 2018; and HeartSheet, an autologous skeletal muscle cell sheet conditionally approved in 2015 for severe ischemic heart failure, had its full-approval application rejected in July 2024 0004. These are dated regulatory examples, not a list of all currently available treatments. HeartSheet is not an MSC product.

An “approved in Japan” claim needs four details to mean anything: product, indication, approval type, and date.

Approval, legality, and evidence are different things

Term What it means What it does not mean
Approved A regulator has cleared a specific product for a specific use Clearance for every disease, or for a clinic’s own version
Legal The provider may offer the service under local rules That the treatment has proven benefit
Clinical evidence Human study findings about benefits, lack of benefit, or harms in a defined population That the findings are strong, positive, or applicable to another product
In a clinical trial The intervention is being studied under a protocol That it is safe, effective, or free
Marketed Someone is selling it That it is approved or evidence-based

How to read the evidence for a treatment

A long bibliography does not answer the key question: did the studies test the same cell type, processing, dose, route, and patient group? Lab and animal findings can support a mechanism, but they cannot establish benefit in people.

Study size and disease severity matter too. A small study in mild knee osteoarthritis cannot establish the result in advanced disease or reliably detect uncommon harms.

Garza and colleagues reported a multisite, double-blind randomized trial in 39 adults with symptomatic knee osteoarthritis. Participants were assigned equally to high-dose SVF, low-dose SVF, or placebo. SVF was obtained by liposuction, processed, and injected into the knee during the same visit. The study measured WOMAC scores, a questionnaire assessing knee pain, stiffness, and function, and MRI findings at baseline, six months, and twelve months 32109160.

The abstract reports median WOMAC percentage improvements of 83.9%, 51.5%, and 25.0% at six months for high dose, low dose, and placebo, respectively. At twelve months, the figures were 89.5%, 68.2%, and 0%. Both SVF groups differed statistically from placebo at both follow-ups. MRI review found no change in cartilage thickness, and no serious adverse events were reported 32109160. These percentages describe changes in symptom scores, not the percentage of patients cured or the amount of cartilage restored.

The findings support a symptom-improvement signal for this preparation in this small trial, not proof of cartilage regeneration or effectiveness of other MSC products. With only 39 participants, the absence of reported serious events does not rule out uncommon harms. The abstract does not provide enough information to verify exact cell doses, trial phase, attrition, or a complete adverse-event breakdown; those require the full report.

For a concrete comparison, put the clinic’s product specification beside that study: autologous fat-derived SVF, one intra-articular injection, adults with symptomatic knee osteoarthritis, and follow-up through twelve months. If the clinic instead offers IV donor MSCs, this trial does not establish benefit for that offer. If it cites “83.9% improvement,” ask whether it means the study’s median score change rather than a success rate. This is a document-based comparison, not a report of a patient’s outcome.

Early-phase trials generally emphasize safety, dosing, or feasibility; later trials may test efficacy. Phase alone does not settle quality. Look for appropriate controls, prespecified endpoints, sufficient follow-up, replication, and transparent funding and conflicts of interest. Uncontrolled results cannot reliably separate treatment effects from natural recovery, standard care, or placebo effects.

When you read a study, or a clinic’s summary of one, run through this list:

  • The population. Does it match your diagnosis, stage, age, and prior treatment?
  • The product. Same cell type, source, processing, dose, and route?
  • The comparison. Was there a placebo, sham, or standard-care group?
  • The endpoint. Did it measure something that matters to you, or just a lab value?
  • The follow-up. Long enough to tell whether the effect lasts?
  • The harms. Were adverse events reported, serious ones included?
  • The size. How many people took part — and how many dropped out?
  • The source. Peer-reviewed paper, regulator, or the clinic’s own brochure?

Registration records a study; it does not validate the intervention or grant marketing authorization Important patient and consumer information about regenerative medicine therapies. PubMed inclusion is not a quality guarantee. A journal abstract can confirm selected reported results, but it cannot replace a full methods-and-results assessment.

What to ask before you pay

Bring a written treatment plan and the cited study to an independent clinician. Use these questions to identify what is known, what differs, and what remains uncertain.

  1. What exactly will I receive? Ask for the cell type, tissue source, autologous or allogeneic origin, whether the cells were grown in culture, the passage number (how many times they were grown) or other processing details, the cell count, and the viability at release.
  2. Where do the cells come from? For donor products, ask about donor screening and whether compatibility matching is required for that product. For your own cells, ask how collection works and what happens if the sample is inadequate.
  3. How was the product tested? Ask for available batch-release documentation covering identity, viability, sterility, endotoxin, and product-appropriate potency testing. If a result is not available before administration, ask why and what safeguards apply. A certificate alone does not prove clinical benefit.
  4. What is the dose and the schedule? Pin down the total cell number, cells per kilogram where relevant, viability, and the number of doses. A higher cell count does not prove a better result.
  5. How will it be delivered? Intravenous, into the joint, intrathecal, or on the skin? Who performs it, and which facility handles complications?
  6. What human evidence exists in people like me? Ask for the trial phase, the headcount, the control group, the main endpoint, the follow-up, and the adverse events. Animal or lab work is not human evidence.
  7. What is the regulatory status here? An approved product, a clinical trial, or a provision plan or other local registration? Get the product name, the indication, the approval type, and the plan or trial number in writing.
  8. What are the known risks, and who manages them? Ask about infusion reactions, infection, immune reactions, ectopic tissue — and who takes care of you if trouble starts after you go home.
  9. What alternatives exist? How does it stack up against standard care, and what happens if you pause effective treatment? Newer or pricier is not the same as better.
  10. What is the total cost and the follow-up plan? Insist on an itemized quote covering each step that drives treatment costs in Japan: collection, processing, testing, visits, imaging, aftercare, complication management. Who handles follow-up, and for how long? Traveling for treatment? Ask who manages complications once you are back home.
  11. What is in writing? Take home the consent form, the product information, and every benefit claim on paper. A guaranteed cure should worry you, not reassure you.

Red flags

  • One product sold for a dozen unrelated diseases, with no separate evidence for each.
  • The clinic claims zero side effects, or says your own cells are always safe.
  • “Approved” gets thrown around with no product, indication, or regulator named.
  • A trial registration or a clinic registration number is waved around as proof the treatment works.
  • The pitch leans on “stem cells know where to go” or a “special protocol” that no outsider can check.
  • Before-and-after photos and testimonials stand in for real evidence.
  • You must pay today, a cash discount expires tonight, or a second opinion is discouraged.
  • No clear treatment protocol, no explanation of product testing, no complication plan, or no clinician responsible for follow-up.
  • Exosomes, “stem cell” pills, or “stem cell activators” are sold as equals of a transplant or an injected cell product.
  • The clinic promises a cure, tells you to drop standard treatment, or skips diagnosis entirely.

The bottom line

Ryoncil’s pediatric GVHD response rates and the Garza trial’s knee symptom-score changes measure different outcomes in different populations. They cannot be used to rank the treatments against each other. Nor can either set of results be assigned to another product simply because it is called a stem cell treatment.

Are all stem cell treatments the same? No. Before comparing prices, match the cell type and source, processing, dose, route, diagnosis, human evidence, and local regulatory status. For US approval claims, start with the FDA’s list of licensed cellular and gene therapy products, then read the specific product’s indication and labeling Approved cellular and gene therapy products.

If important details are missing, obtain them in writing and seek an independent medical opinion before committing. Do not stop effective treatment on the strength of a marketing claim.

This article provides general information, not a diagnosis, individual treatment recommendation, or assessment of a specific clinic. A qualified clinician familiar with your medical history should help you weigh established alternatives, potential benefits, and risks.

Still weighing two very different offers?

Contact the clinic team about appointment arrangements and which medical records to prepare. Individual treatment questions require a physician’s assessment.

Ask about a consultation

Sources

  1. US Food and Drug Administration. FDA Approves First Mesenchymal Stromal Cell Therapy to Treat Steroid-refractory Acute Graft-versus-host Disease. December 18, 2024. Accessed October 27, 2026.
  2. National Cancer Institute. Stem Cell Transplants in Cancer Treatment. Accessed October 27, 2026.
  3. US Food and Drug Administration. Important Patient and Consumer Information About Regenerative Medicine Therapies. Content current as of April 8, 2024. Accessed October 27, 2026.
  4. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. Cytotherapy. 2006;8(4):315–317. Accessed October 23, 2026.
  5. Garza JR, Campbell RE, Tjoumakaris FP, et al. Clinical Efficacy of Intra-articular Mesenchymal Stromal Cells for the Treatment of Knee Osteoarthritis: A Double-Blinded Prospective Randomized Controlled Clinical Trial. American Journal of Sports Medicine. 2020;48(3):588–598. Published abstract, accessed via Europe PMC October 27, 2026.
  6. Pharmaceuticals and Medical Devices Agency, Japan. Temcell HS Inj. review report. 2015, “Indication or performance” and “Dosage and administration or method of use.” Accessed October 27, 2026.
  7. Pharmaceuticals and Medical Devices Agency, Japan. Stemirac review report. 2018, “Indication or Performance” and “Dosage and Administration or Method of Use.” Accessed October 27, 2026.
  8. US Food and Drug Administration. RYONCIL (remestemcel-L-rknd) Prescribing Information. December 2024, section 6.1. Accessed October 23, 2026; indexed FDA label excerpt rechecked October 27, 2026.
  9. Ministry of Health, Labour and Welfare, Japan. Overview of submission of regenerative medicine provision plans (in Japanese). Accessed October 27, 2026.
  10. Pharmaceuticals and Medical Devices Agency, Japan. Regenerative Medical Products. Accessed October 27, 2026.
  11. Pharmaceuticals and Medical Devices Agency, Japan. Review Reports: Regenerative Medical Products. Accessed October 27, 2026.
  12. US Food and Drug Administration. Approved Cellular and Gene Therapy Products. Accessed October 27, 2026.